Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

Civacir® (Civacir) - Prophylaxis hepatitis C reinfection
Tregalizumab (BT-061) - Plaque psoriasis
Tregalizumab (BT-061) - Rheumatoid arthritis
IgM Concentrate (BT-086) - Severe community acquired pneumonia
Indatuximab Ravtansine (BT-062) - Multiple myeloma
Indatuximab Ravtansine (BT-062) - Solid tumors
(BT-063) - Systemic lupus erythematosus
Fibrinogen (BT-524) - Congenital and acquired fibrinogen deficiency
Cytotect 70 (BT-084) - Congenital CMV infection prophylaxis

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Further information

Press releases

Correction of a release from 14.08.2015, 11:11 CET - Bi...

14.08.2015, PVR

On August 13, 2015, BayernInvest Kapitalverwaltungsgesellschaft mbH, 80333 Munich, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on ... [More]

Release according to Article 26, Section 1 of the WpHG ...

14.08.2015, PVR

On August 13, 2015, Bayerininvest Kapitalverwaltungsgesellschaft mbH, 80333 Munich, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on ... [More]

Biotest increases revenues in first half year 2015 by 8...

11.08.2015, News

Biotest increases revenues in first half year 2015 by 8.9% - Clinical development of BT-061 will be discontinued - Capacity expansion at headquarter Dreieich on schedule - Board of ... [More]

Biotest stock split becomes effective as scheduled - fi...

14.07.2015, News

Biotest stock split becomes effective as scheduled - first trading day on July 15 - Stock listing and shareholders' deposits will be changed on July 15th in a ratio 1:3 - Shares in ... [More]

Biotest AG reorganises stock exchange listing due to sh...

08.07.2015, News

Biotest AG reorganises stock exchange listing due to share split on 15 July 2015 - Share split at a ration of 1:3 - By share split and capital increase from company's funds the ... [More]

Biotest and CEVEC Pharmaceuticals enter into a License ...

01.07.2015, News

Biotest and CEVEC Pharmaceuticals enter into a License Agreement regarding a cell line system for the production of tailor-made proteins - The agreement relates to CEVEC's proprietary ... [More]

Biotest's IgM Concentrate shows encouraging results in ...

30.06.2015, News

Biotest's IgM Concentrate shows encouraging results in life-threatening pneumonia - Phase II trial with IgM Concentrate completed in patients with severe community acquired ... [More]

DGAP-NVR: Biotest AG: Release according to Article 26a ...

30.06.2015, NVR

Biotest AG hereby announces that at the end of the month June 2015 the number of Voting Rights amounts to a total of 19785726 Voting Rights. It is planned that the technical execution will take ... [More]

Biotest regains rights to Tregalizumab (BT-061)

24.06.2015, News

Biotest regains rights to Tregalizumab (BT-061) - AbbVie exercised its rights to opt-out of the worldwide license, development and commercialisation agreement Dreieich, ... [More]

Biotest AG and Affibody AB enter into a Research Licens...

01.06.2015, News

Biotest AG and Affibody AB enter into a Research License and Option Agreement regarding the Albumod(TM) technology platform - Affibody's Albumod(TM) technology is designed to prolong the ... [More]

Annual general meeting approves increase of dividend an...

07.05.2015, News

Biotest AG: Annual general meeting approves increase of dividend and a share split - Dividend payment of EUR 0.60 per ordinary share and EUR 0.66 per preference share - Share split with ... [More]

Biotest increases revenues by 16,6%

07.05.2015, News

Biotest increases revenues by 16,6% - Higher Sales in the US - Capacity expansion at headquarter Dreieich in schedule Dreieich, 7 May 2015. The Biotest Group again succeeded to increase ... [More]

Biotest Phase IIb study of Tregalizumab (BT-061) in mo...

24.04.2015, News

Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - potential one time effect of up to - EUR 30 million - No safety ... [More]

Biotest Phase IIb study of Tregalizumab (BT-061) in mod...

24.04.2015, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - ... [More]

Biotest presents new clinical and preclinical results o...

23.04.2015, News

Biotest presents new clinical and preclinical results of Civacir(R) at The 50th International Liver Congress 2015 in Vienna - Preliminary clinical results suggest that Civacir(R) reduces the ... [More]

Biotest proves effective protection from Hepatitis B vi...

23.04.2015, News

Biotest proves effective protection from Hepatitis B virus reinfection after liver transplantation in "ZEUS" study with subcutaneous hepatitis B immunoglobulin Zutectra(R) - The ... [More]

Biotest announces the opening of a plasma collection fa...

13.04.2015, News

Biotest announces the opening of a plasma collection facility in Conway, Arkansas, US and the relocation of it's plasma collection Facility in San Antonio, Texas, US - Total number of plasma ... [More]

Biotest increases sales by 16.2%

24.03.2015, News

Biotest increases sales by 16.2% - Earnings before interest and tax (EBIT) at EUR 53.4 million - Expansion project "Biotest Next level" in timeline and budget - Share split with the ... [More]

Biotest AG: Biotest proposes capital increase from capi...

17.03.2015, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest AG: Biotest proposes capital increase from capital funds and share split to General Meeting - Proposed capital ... [More]

DGAP-AFR: Biotest AG: Announcement according to Article...

10.03.2015, AFR

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Annual financial report Date of disclosure / German: March 24, 2015 Date of disclosure / English: ... [More]

Careers

Careers

Passionate to help us save lives?

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialigue with the financial community.